Chao Angel, Wang Tzu-Hao
Department of Obstetrics and Gynecology, Linkou Medical Center, Taoyuan, Taiwan.
Department of Obstetrics and Gynecology, Linkou Medical Center, Taoyuan, Taiwan; Genomic Medicine Research Core Laboratory, Linkou Medical Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Taiwan J Obstet Gynecol. 2016 Feb;55(1):3-8. doi: 10.1016/j.tjog.2015.12.004.
The successful development of the proteasome inhibitor bortezomib as an anticancer drug has improved survival in patients with multiple myeloma. With the emergence of the newly US Food and Drug Administration-approved proteasome inhibitor carfilzomib, ongoing trials are investigating this compound and other proteasome inhibitors either alone or in combination with other chemotherapy drugs. However, in solid tumors, the efficacy of proteasome inhibitors has not lived up to expectations. Results regarding the potential clinical efficacy of bortezomib combined with other agents in the treatment of solid tumors are eagerly awaited. Recent identification of the molecular mechanisms (involving apoptosis and autophagy) by which bortezomib and cisplatin can overcome chemotherapy resistance and sensitize tumor cells to anticancer therapy can provide insights into the development of novel therapeutic strategies for patients with solid malignancies.
蛋白酶体抑制剂硼替佐米作为一种抗癌药物的成功研发，已提高了多发性骨髓瘤患者的生存率。随着美国食品药品监督管理局新批准的蛋白酶体抑制剂卡非佐米的出现，正在进行的试验正在单独或与其他化疗药物联合研究该化合物及其他蛋白酶体抑制剂。然而，在实体瘤中，蛋白酶体抑制剂的疗效并未达到预期。人们急切期待硼替佐米与其他药物联合治疗实体瘤的潜在临床疗效的结果。最近对硼替佐米和顺铂能够克服化疗耐药性并使肿瘤细胞对抗癌治疗敏感的分子机制（涉及凋亡和自噬）的鉴定，可为实体恶性肿瘤患者新治疗策略的开发提供见解。
